Grace Therapeutics (GRCE) Operating Income (2019 - 2026)

Grace Therapeutics has disclosed Operating Income across 8 years of filings, most recently posting -$15.9 million for Q2 2026.

• In Q2 2026, Operating Income fell 415.11% year-over-year to -$15.9 million; the TTM figure through Jun 2026 stood at -$23.9 million (down 61.43% YoY), while the FY2026 annual figure was -$11.1 million, up 33.59% from the prior year.
• Operating Income came in at -$15.9 million for Q2 2026 at Grace Therapeutics, down from -$3.0 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$2.1 million in Q3 2023 to a low of -$38.1 million in Q1 2023.
• Average Operating Income over 5 years is -$6.3 million, with a median of -$4.0 million recorded in 2022.
• Year-over-year, Operating Income plunged 764.71% in 2023 and surged 91.43% in 2024.
• Over 5 years, Operating Income stood at -$4.2 million in 2022, then gained by 28.32% to -$3.0 million in 2023, then dropped by 21.72% to -$3.7 million in 2024, then soared by 33.88% to -$2.4 million in 2025, then sank by 549.94% to -$15.9 million in 2026.
• Per Business Quant data, the three most recent Operating Income figures were -$15.9 million in Q2 2026, -$3.0 million in Q1 2026, and -$2.4 million in Q4 2025.